Coronavirus (COVID-19) updates for UC San Diego Health patients and visitors. Learn More

Menu
Search

UC San Diego Sulpizio Cardiovascular Center Opens to Public

 

August 08, 2011  |  

UC San Diego Sulpizio Cardiovascular Center (SCVC) will officially open its doors to the public on Monday, August 8 after the California Department of Public Health (CDPH) certified the SCVC for patient care.  The region’s first cardiovascular center is now accessible to the tens of thousands of Californians who are at risk for or suffer from heart disease and stroke.  
 

SCVC

The Sulpizio Cardiovascular Center

The first cardiac inpatients transferred from UC San Diego's medical centers on Sunday, July 31.  The cardiovascular hybrid operating rooms, catheterization labs and procedural treatment unit (PTU) are in full operation as well as the ambulatory clinics.
 
“The SCVC is at the forefront of modern efforts to combat heart and vascular diseases, the most common causes of disability and mortality within our population.  As leaders and teachers in this field, we offer advanced diagnostics, novel treatments and access to a number of clinical trials not available anywhere else in the San Diego region,” said Kirk L. Peterson, MD, director, Sulpizio Cardiovascular Center and Professor of Cardiology and Medicine at the UCSD School of Medicine.
 
According to the American Heart Association, heart disease and stroke are the number one and number three causes of death, and a leading cause of disability, among Californians. Compared to the nation, California has slightly above average rates for coronary heart disease and stroke mortality.
 
“The opening of the SCVC is a milestone development for UC San Diego Health System,” explained Tom Jackiewicz, CEO of UC San Diego Health System.  “In the next five years, we will open Jacobs Medical Center, the Clinical and Translational Research Institute (CTRI), and the Center for the Future of Surgery. Our journey continues today, as we welcome patients, neighbors and supporters to the one place in San Diego where cardiovascular care is fully integrated.”
 
With the SCVC open, patients now have access to a spectacular facility with 54 new inpatient beds, four new cardiovascular ORs, four new cardiac catheterization laboratories, a new non-invasive cardiovascular laboratory, and outpatient clinics.  Nearly 100 new employees have been hired including nurses, telephone operators, technicians, security and a nutritionist.  
 
“We also want to take this opportunity to thank the Sulpizio Family again for its generous contribution and continuing support of our efforts to deliver the very best in cardiovascular care and treatment,” said Peterson.  “We believe that their gift, and all our donors’ support, will translate into improved, lifesaving care for cardiovascular patients who come to UC San Diego from near and far.” 

 

About the UC San Diego Sulpizio Cardiovascular Center

UC San Diego Sulpizio Cardiovascular Center is dedicated to innovative care and the prevention, diagnosis and treatment of cardiovascular disease. The state-of-the-art facility, which opened in La Jolla in 2011, is the region’s first academic-based facility to combine all heart and vascular-related services, programs and technology under one roof.

# # #

Media contact: Kim Edwards, 619-543-6163, kedwards@ucsd.edu


Related Specialties

Sulpizio Cardiovascular Center


Media Contact

Share This Article


Related News

5/26/2020
UC San Diego Health has deployed a mobile ECMO life support system to help sustain critically-ill patients during the pandemic.
5/21/2020
During COVID-19, UC San Diego Health expanded telehealth to provide patients with safe and convenient access to appointments with their health care providers. Video visits expanded by more than 50-fol ...
5/19/2020
UC San Diego researchers have identified small molecules in the blood of asymptomatic pregnant women that may predict risk for preeclampsia, responsible for a significant proportion of maternal and ne ...
5/15/2020
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites ...



Follow Us